The Liquid Scan Platform

BioFluidica, in conjunction with the NIH National Biotechnology Resource Center of BioModular Multiscale Systems for Precision medicine, is developing the next generation disease diagnostic platform. Our technology is based on the extensive portfolio of intellectual property generated by the Company's founder, Professor Steven A. Soper. Dr. Soper has ten years of experience in developing and clinically verifying the utility of new platforms for the liquid biopsy area.

Like a CT or MRI scan, which surveys the whole body for the presence of disease, Biofluidica's Liquid Scan Technology searches a blood sample for rare biomarkers, such as CTCs, cfDNA and/or exosomes. However, it is not enough to recover a few biomarkers and count their presence. What is important is to select the biomarkers, eliminate non-specific background particles, and analyze the recovered biomarkers with molecular methods to assign correct therapeutics. The technologies developed by BioFluidica can be used for point-of-care testing in hospitals, CLIA labs, and research institutes allowing for widespread adoption.

The leap in technological advantages, provided by BioFluidica's method, was made possible through the development of a patented microfluidic chip. This chip provides efficient capture, release, enumeration and molecular analysis of circulating biomarkers from whole blood, including viable cells. Our technology allows high-throughput, low-cost manufacturing, precision, which results in low test costs, which can more readily be covered by insurance. Our platform is designed to optimize biomarker binding, which facilitates highly successful recovery of rare biomarkers. At the same time, our system minimizes non-intended and non-specific binding of unwanted white blood cells and other blood impurities. A patented cleavable linker system releases bound biomarkers for labeless counting. In the case of CTCs, the platform exceeds 95% recovery and offers more than 80% purity, thereby enabling advanced molecular diagnostic testing of even the rarest cancer cells.